Philips Introduces ECG for Decentralized Trials
New solution looks to improve recruitment, compliance, and retention.
Royal Philips has announced the introduction of an at-home, 12-lead electrocardiogram (ECG) solution for use in decentralized clinical trials. The clinical-grade solution pairs data readings comparable to clinical, site-based ECGs with Philips cloud-based data collection and analysis services.
Leveraging PCA 500 ECG patch data recording technology, the at-home solution allows clinical trial participants to record data with quality comparable to site-based ECGs at home. The solution’s body-worn patch ensures compliant 12-lead ECG placement and near real-time, highly secure data transmission without the need for recurring site visits, onsite technician, or home nurses.
Read more about the new solution here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
